spironolactone has been researched along with 8-epi-prostaglandin f2alpha in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (66.67) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Aso, Y; Inukai, T; Matsumoto, S; Takebayashi, K | 1 |
| Knap, N; Larczynski, W; Neuwelt, A; Renke, M; Rutkowski, B; Rutkowski, P; Tylicki, L; Wozniak, M | 1 |
| Adiyiah, J; Bayorh, MA; Eatman, D; Lyn, D; Rollins-Hairston, A | 1 |
2 trial(s) available for spironolactone and 8-epi-prostaglandin f2alpha
| Article | Year |
|---|---|
Aldosterone blockade attenuates urinary monocyte chemoattractant protein-1 and oxidative stress in patients with type 2 diabetes complicated by diabetic nephropathy.
Topics: Chemokine CCL2; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Dinoprost; Humans; Mineralocorticoid Receptor Antagonists; Oxidative Stress; Spironolactone | 2006 |
Spironolactone attenuates oxidative stress in patients with chronic kidney disease.
Topics: Adult; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Antioxidants; Benzimidazoles; Benzoates; Chronic Disease; Cilazapril; Creatinine; Cross-Over Studies; Dinoprost; Diuretics; Female; Humans; Hydrochlorothiazide; Kidney Diseases; Male; Mineralocorticoid Receptor Antagonists; Oxidative Stress; Spironolactone; Telmisartan | 2008 |
1 other study(ies) available for spironolactone and 8-epi-prostaglandin f2alpha
| Article | Year |
|---|---|
Eplerenone suppresses aldosterone/ salt-induced expression of NOX-4.
Topics: Acetophenones; Aldosterone; Animals; Blood Pressure; Blotting, Western; Body Weight; Dinoprost; Eplerenone; Male; NADPH Oxidase 4; NADPH Oxidases; Nitric Oxide; Protein Subunits; Proteinuria; Rats; Rats, Inbred Dahl; Sodium; Sodium Chloride, Dietary; Spironolactone; Systole; Urinalysis | 2011 |